DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, ISEE, STXS, BPMC, RVMD, and represent 33.26% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: DAWN (+$6.1M), TSVT (+$5.0M), Ascendis Pharma A/s, TNDM, MRUS, KURA, CYTK, MORF, LYRA, KROS.
- Started 8 new stock positions in ELEV, TNDM, PRCT, LYRA, Ascendis Pharma A/s, TSVT, NVRO, DAWN.
- Reduced shares in these 10 stocks: KRTX (-$7.9M), Cardiovascular Systems (-$5.7M), BHVN (-$5.1M), APLS, DICE, RVMD, EWTX, XENE, THRX, ORIC.
- Sold out of its positions in APLS, Cardiovascular Systems, GNFT, IKNA, ORIC, REUN, THRX.
- DAFNA Capital Management was a net buyer of stock by $932k.
- DAFNA Capital Management has $366M in assets under management (AUM), dropping by 9.65%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 73 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p Biotech Etf Etf (XBI) | 12.9 | $47M | 565k | 83.20 |
|
|
| Iveric Bio (ISEE) | 6.6 | $24M | 613k | 39.34 |
|
|
| Stereotaxis Com New (STXS) | 5.7 | $21M | 14M | 1.53 |
|
|
| Blueprint Medicines (BPMC) | 4.3 | $16M | -3% | 252k | 63.20 |
|
| Revolution Medicines (RVMD) | 3.7 | $14M | -11% | 512k | 26.75 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 3.6 | $13M | 103k | 126.96 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 3.3 | $12M | 135k | 89.25 |
|
|
| Morphic Hldg (MORF) | 3.2 | $12M | +15% | 207k | 57.33 |
|
| Ideaya Biosciences (IDYA) | 3.1 | $11M | +2% | 480k | 23.50 |
|
| Cytokinetics Com New (CYTK) | 3.0 | $11M | +20% | 333k | 32.62 |
|
| Xenon Pharmaceuticals (XENE) | 3.0 | $11M | -11% | 281k | 38.50 |
|
| Merus N V (MRUS) | 2.8 | $10M | +35% | 385k | 26.33 |
|
| Syndax Pharmaceuticals (SNDX) | 2.6 | $9.4M | 451k | 20.93 |
|
|
| Karuna Therapeutics Ord (KRTX) | 2.5 | $9.1M | -46% | 42k | 216.85 |
|
| Dex (DXCM) | 2.4 | $8.7M | 68k | 128.51 |
|
|
| Sage Therapeutics (SAGE) | 2.3 | $8.5M | 180k | 47.02 |
|
|
| Neurocrine Biosciences (NBIX) | 1.9 | $7.0M | 75k | 94.30 |
|
|
| AtriCure (ATRC) | 1.7 | $6.2M | 126k | 49.36 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 1.7 | $6.1M | NEW | 507k | 11.94 |
|
| Dice Therapeutics (DICE) | 1.6 | $5.9M | -31% | 128k | 46.46 |
|
| Nurix Therapeutics (NRIX) | 1.5 | $5.6M | 557k | 9.99 |
|
|
| Kalvista Pharmaceuticals (KALV) | 1.5 | $5.5M | 611k | 9.00 |
|
|
| 2seventy Bio Common Stock (TSVT) | 1.4 | $5.0M | NEW | 496k | 10.12 |
|
| Viking Therapeutics (VKTX) | 1.3 | $4.8M | -7% | 294k | 16.21 |
|
| Accuray Incorporated (ARAY) | 1.3 | $4.7M | 1.2M | 3.87 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $4.6M | +28% | 226k | 20.31 |
|
| Century Therapeutics (IPSC) | 1.1 | $4.1M | 1.3M | 3.16 |
|
|
| Edgewise Therapeutics (EWTX) | 1.1 | $4.0M | -29% | 519k | 7.75 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.1 | $4.0M | +3% | 569k | 7.04 |
|
| Alector (ALEC) | 1.0 | $3.8M | +7% | 639k | 6.01 |
|
| Kura Oncology (KURA) | 1.0 | $3.8M | +225% | 358k | 10.58 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.0 | $3.6M | NEW | 4.0M | 0.91 |
|
| Mirati Therapeutics (MRTX) | 0.9 | $3.4M | +28% | 95k | 36.13 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.9 | $3.1M | 122k | 25.52 |
|
|
| Axogen (AXGN) | 0.8 | $3.0M | 332k | 9.13 |
|
|
| Mediwound Shs New (MDWD) | 0.8 | $2.7M | 258k | 10.66 |
|
|
| Tandem Diabetes Care Com New (TNDM) | 0.7 | $2.7M | NEW | 110k | 24.54 |
|
| Mersana Therapeutics (MRSN) | 0.7 | $2.7M | +58% | 811k | 3.29 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.6 | $2.2M | -20% | 930k | 2.38 |
|
| Galapagos Nv Spon Adr (GLPG) | 0.6 | $2.1M | 53k | 40.66 |
|
|
| Adicet Bio (ACET) | 0.5 | $1.9M | 797k | 2.43 |
|
|
| Keros Therapeutics (KROS) | 0.5 | $1.9M | +146% | 48k | 40.18 |
|
| Regulus Therapeutics (RGLS) | 0.4 | $1.6M | +99% | 1.1M | 1.47 |
|
| Vigil Neuroscience (VIGL) | 0.4 | $1.6M | 172k | 9.40 |
|
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.4 | $1.5M | 941k | 1.62 |
|
|
| Lyra Therapeutics (LYRA) | 0.4 | $1.5M | NEW | 361k | 4.11 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.4 | $1.3M | -7% | 1.0M | 1.32 |
|
| Iteos Therapeutics (ITOS) | 0.4 | $1.3M | 99k | 13.24 |
|
|
| Brainsway Sponsored Ads (BWAY) | 0.3 | $1.2M | +6% | 505k | 2.28 |
|
| Sutro Biopharma (STRO) | 0.3 | $1.1M | +186% | 243k | 4.65 |
|
| Larimar Therapeutics (LRMR) | 0.3 | $1.1M | +47% | 350k | 3.13 |
|
| Astria Therapeutics (ATXS) | 0.3 | $1.1M | +82% | 128k | 8.33 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.3 | $996k | +50% | 77k | 12.96 |
|
| Surface Oncology (SURF) | 0.3 | $957k | 1.1M | 0.87 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.2 | $838k | 266k | 3.15 |
|
|
| Pardes Biosciences (PRDS) | 0.2 | $779k | -10% | 430k | 1.81 |
|
| Nevro (NVRO) | 0.2 | $712k | NEW | 28k | 25.42 |
|
| Elevation Oncology (ELEV) | 0.2 | $684k | NEW | 450k | 1.52 |
|
| Neuronetics (STIM) | 0.2 | $675k | 314k | 2.15 |
|
|
| Spruce Biosciences (SPRB) | 0.2 | $671k | 312k | 2.15 |
|
|
| Biohaven (BHVN) | 0.1 | $505k | -91% | 21k | 23.92 |
|
| Masimo Corporation (MASI) | 0.1 | $494k | 3.0k | 164.55 |
|
|
| Compass Therapeutics (CMPX) | 0.1 | $372k | 117k | 3.18 |
|
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $345k | 193k | 1.79 |
|
|
| Nextcure (NXTC) | 0.1 | $338k | 188k | 1.80 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $325k | 351k | 0.93 |
|
|
| Medicenna Therapeutics Corp. (MDNA) | 0.1 | $318k | 660k | 0.48 |
|
|
| Procept Biorobotics Corp (PRCT) | 0.1 | $283k | NEW | 8.0k | 35.35 |
|
| Kinnate Biopharma (KNTE) | 0.1 | $243k | 80k | 3.03 |
|
|
| Compugen Ord (CGEN) | 0.1 | $234k | 205k | 1.14 |
|
|
| Lineage Cell Therapeutics In (LCTX) | 0.1 | $197k | 140k | 1.41 |
|
|
| Spero Therapeutics (SPRO) | 0.0 | $181k | 125k | 1.45 |
|
|
| Inogen (INGN) | 0.0 | $173k | 15k | 11.55 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022
- DAFNA Capital Management 2021 Q4 filed Feb. 14, 2022
- DAFNA Capital Management 2021 Q3 filed Nov. 15, 2021
- DAFNA Capital Management 2021 Q2 filed Aug. 16, 2021
- DAFNA Capital Management 2021 Q1 filed May 17, 2021
- DAFNA Capital Management 2020 Q4 filed Feb. 16, 2021
- DAFNA Capital Management 2020 Q3 filed Nov. 16, 2020
- DAFNA Capital Management 2020 Q2 filed Aug. 14, 2020
- DAFNA Capital Management 2020 Q1 filed May 15, 2020
- DAFNA Capital Management 2019 Q4 filed Feb. 14, 2020
- DAFNA Capital Management 2019 Q3 filed Nov. 14, 2019